Clearside Biomedical, Inc. (CLSD) Dividend History

Company News

• Clearside Biomedical Opens Registration for Suprachoroidal - GlobeNewswire

  Clearside Biomedical is hosting a virtual key opinion leader (KOL) event on suprachoroidal drug delivery, focusing on its potential in treating neovascular age-related macular degeneration (wet AMD) and ongoing clinical programs.

  GlobeNewswire Inc.
• Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

  - Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET -

  GlobeNewswire Inc.
• Why Is Clearside Biomedical Stock Gaining Today?

  Oppenheimer initiated coverage on Clearside Biomedical Inc (NASDAQ:CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space. Oppenheimer writes, “We consider Clearside a pioneer in suprachoroidal delivery via its suprachoroidal Microinjector that improves delivery of therapies for retinal diseases.” Suprachoroidal drug delivery is an ocular route of drug administration. The analyst writes that intravitreal injections have traditionally been the standard for delivering retinal treatments, but they can cause issues like uncontrolled dispersion. Meanwhile, SCS injections provide a more targeted and compartmentalized delivery directly into the chorioretinal tissues, ensuring high concentrations and extended effectiveness. Oppenheimer has initiated the coverage with an Outperform rating and a price ...Full story available on Benzinga.com

  Benzinga

  Featured Companies: BLCO RGNX
• Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

  - Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications -

  GlobeNewswire Inc.
• Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

  - Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery -

  GlobeNewswire Inc.